Paratek Pharmaceuticals logo
Paratek Pharmaceuticals PRTK
report update icon

Quarterly report 2023-Q2
added 05-23-2026

Paratek Pharmaceuticals Accounts Receivables | PRTK

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.
Examples of accounts receivable
  • Customers have not paid invoices for delivered products
  • An advance has been paid to a supplier, but goods have not yet been received
  • Employees have not reported on accountable amounts
  • The government must refund tax overpayments
  • Outstanding loans issued
Importance of accounts receivable in company analysis
  1. Asset quality
    Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
  2. Impact on cash flow
    Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
  3. Assessment of management efficiency
    The following accounts receivable turnover ratios are commonly used:
    Receivables turnover = Revenue / Average accounts receivable
    (the higher — the better)

    Days Sales Outstanding (DSO) = 365 / Turnover
    (the fewer days — the faster customers pay)

    If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Paratek Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
74.7 M 29.4 M 11.9 M 8.48 M 41 K 5.04 M - 745 K 4.43 M 243 K 168 K 288 K - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
74.7 M 41 K 12.3 M

Quarterly Accounts Receivables Paratek Pharmaceuticals

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
42.3 M 36.9 M 74.7 M 29.4 M 28.5 M 24.7 M 29.4 M 21.9 M 55.6 M 15.9 M 11.9 M 13 M 8.66 M 10.9 M 8.48 M 3.98 M 2.56 M 2.2 M 41 K 22 K 19 K 50 K 5.04 M 5.04 M 5.04 M 5.04 M - 230 K 85 K 488 K 745 K 270 K 496 K 391 K 4.43 M 4.43 M 4.43 M 4.43 M 243 K - - - 168 K - - - 288 K - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
74.7 M 19 K 11.6 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer Accounts Receivables Price % 24h Market Cap Country
InMed Pharmaceuticals InMed Pharmaceuticals
INM
1.95 M $ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
308 M $ 12.36 -9.55 % $ 799 M usaUSA
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
831 M $ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
Johnson & Johnson Johnson & Johnson
JNJ
17.2 B $ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
5.55 M $ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
2.4 M $ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
10 M $ 1.0 -5.17 % $ 87.1 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
61 M $ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
17.8 M $ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
25 K $ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
2.02 M $ 27.36 -2.15 % $ 1.82 B usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
891 K $ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
643 K $ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
17.8 B $ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
211 M $ 24.73 -1.9 % $ 783 M usaUSA
Curis Curis
CRIS
3.35 M $ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
171 M $ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
700 K $ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
13.2 M $ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
1 K $ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
123 M $ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
38.4 M $ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
1.09 M $ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
11.8 B $ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
184 M $ 195.25 -2.05 % $ 76 B usaUSA
Novartis AG Novartis AG
NVS
12 M $ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
53.7 M $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
2.03 M $ 3.69 -0.67 % $ 281 M usaUSA
Geron Corporation Geron Corporation
GERN
37 M $ 0.87 -4.76 % $ 580 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
78.1 M $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
34 M $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
12.2 M $ 10.69 -4.81 % $ 2.44 B usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
54.1 M $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
2 M $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
6.01 M $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
182 M $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
928 K $ 1.24 -12.34 % $ 4.53 B usaUSA